A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
07 2021
Historique:
accepted: 14 01 2021
pubmed: 18 1 2021
medline: 27 7 2021
entrez: 17 1 2021
Statut: ppublish

Résumé

Whether melanoma in histological contiguity with a naevus [naevus-associated melanoma (NAM)] is distinctly different from melanoma arising de novo remains unclear. To determine whether the characteristics of de novo melanoma differ from NAM and are not due to naevus obliteration in thicker tumours. We conducted a multicentre retrospective study of de novo melanoma and NAM in seven referral centres in Europe, Australia and the USA between 2006 and 2015. In a total of 9474 localized melanomas, de novo melanoma was associated with thicker tumours and body site differences compared with NAM. In the subset of T Clinicopathological and body site differences between de novo melanoma and NAM support the divergent pathway model of development. These differences were also found in thin melanomas, suggesting that de novo melanomas are different from NAM and their differences are not due to the obliteration of naevus remnants in thicker tumours.

Sections du résumé

BACKGROUND
Whether melanoma in histological contiguity with a naevus [naevus-associated melanoma (NAM)] is distinctly different from melanoma arising de novo remains unclear.
OBJECTIVES
To determine whether the characteristics of de novo melanoma differ from NAM and are not due to naevus obliteration in thicker tumours.
METHODS
We conducted a multicentre retrospective study of de novo melanoma and NAM in seven referral centres in Europe, Australia and the USA between 2006 and 2015.
RESULTS
In a total of 9474 localized melanomas, de novo melanoma was associated with thicker tumours and body site differences compared with NAM. In the subset of T
CONCLUSIONS
Clinicopathological and body site differences between de novo melanoma and NAM support the divergent pathway model of development. These differences were also found in thin melanomas, suggesting that de novo melanomas are different from NAM and their differences are not due to the obliteration of naevus remnants in thicker tumours.

Identifiants

pubmed: 33454993
doi: 10.1111/bjd.19819
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101-109

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 British Association of Dermatologists.

Références

Pampena R, Kyrgidis A, Lallas A et al. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol 2017; 77:938-45.e934.
Shain AH, Yeh I, Kovalyshyn I et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015; 373:1926-36.
Bevona C, Goggins W, Quinn T et al. Cutaneous melanomas associated with nevi. Arch Dermatol 2003; 139:1620-4.
Purdue MP, From L, Armstrong BK et al. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005; 14:2015-22.
Bauer J, Buttner P, Murali R et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24:345-51.
Broekaert SM, Roy R, Okamoto I et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010; 23:763-70.
Whiteman DC, Watt P, Purdie DM et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95:806-12.
Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011; 24:879-97.
Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer 2016; 16:345-58.
Elder DE, Bastian BC, Cree IA et al. The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 2020; 144:500-22.
Elder D, Barnhill RL, Bastian BC et al. Melanocytic tumour classification and the pathway concept of melanoma pathogenesis. In: WHO Classification of Skin Tumours (Elder DE, Massi D, Scolyer RA, Willemze R, eds), 4th edn, vol. 11. Lyon: International Agency for Research on Cancer (IARC), 2018; 66-71.
Manrique-Silva E, Reyes-Garcia D, Folgado B et al. The proportion of nevus-associated invasive melanoma differs with Breslow thickness: a cross-sectional study of 1087 cutaneous melanomas. J Am Acad Dermatol 2019; 81:852-4.
Sagebiel RW. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness. J Invest Dermatol 1993; 100:322S-S325.
Dessinioti C, Dimou N, Geller AC et al. Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. J Natl Cancer Inst 2019; 111:1314-22.
Ribero S, Osella-Abate S, Sanlorenzo M et al. Sentinel lymph node biopsy in thick-melanoma patients (N=350): what is its prognostic role? Ann Surg Oncol 2015; 22:1967-73.
Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:472-92.
Austin PC. A tutorial on multilevel survival analysis: methods, models and applications. Int Stat Rev 2017; 85:185-203.
Bataille V, Grulich A, Sasieni P et al. The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer 1998; 77:505-10.
Cust AE, Drummond M, Bishop DT et al. Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure. J Eur Acad Dermatol Venereol 2019; 33:1874-85.
Dessinioti C, Geller AC, Stergiopoulou A et al. nevus count associations with thinner nodular or superficial spreading melanoma. Acta Derm Venereol 2019; 99:614-5.
Duffy DL, Iles MM, Glass D et al. IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am J Hum Genet 2010; 87:6-16.
Cymerman RM, Shao Y, Wang K et al. De novo vs. nevus-associated melanomas: differences in associations with prognostic indicators and survival. J Natl Cancer Inst 2016; 108:djw121.
Shitara D, Tell-Marti G, Badenas C et al. Mutational status of naevus-associated melanomas. Br J Dermatol 2015; 173:671-80.
Lin WM, Luo S, Muzikansky A et al. Outcome of patients with de novo versus nevus-associated melanoma. J Am Acad Dermatol 2015; 72:54-8.
Sheen YS, Liao YH, Lin MH et al. Clinicopathological features and prognosis of patients with de novo versus nevus-associated melanoma in Taiwan. PLOS ONE 2017; 12:e0177126.
Pan Y, Adler NR, Wolfe R, McLean CA, Kelly JW. Nodular melanoma is less likely than superficial spreading melanoma to be histologically associated with a naevus. Med J Aust 2017; 207:333-8.
Clark WH Jr, Elder DE, Guerry DE et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15:1147-65.
Shen S, Wolfe R, McLean CA et al. Characteristics and associations of high-mitotic-rate melanoma. JAMA Dermatol 2014; 150:1048-55.
Olsen CM, Thompson JF, Pandeya N, Whiteman DC. Evaluation of sex-specific incidence of melanoma. JAMA Dermatol 2020; 156:553-60.
Pandeya N, Kvaskoff M, Olsen CM et al. Factors related to nevus-associated cutaneous melanoma: a case-case study. J Invest Dermatol 2018; 138:1816-24.
Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014; 9:239-71.
Menzies AM, Haydu LE, Visintin L et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18:3242-9.
Vu M, Adler NR, Wee E et al. Impact of naevus association on survival for nodular and superficial spreading melanomas. Br J Dermatol 2018; 179:761-2.
Martin-Gorgojo A, Requena C, Garcia-Casado Z et al. Dysplastic vs. common naevus-associated vs. de novo melanomas: an observational retrospective study of 1021 patients. Acta Derm Venereol 2018; 98:556-62.
Haenssle HA, Mograby N, Ngassa A et al. Association of patient risk factors and frequency of nevus-associated cutaneous melanomas. JAMA Dermatol 2016; 152:291-8.
Caini S, Gandini S, Sera F et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer 2009; 45:3054-63.
Ribero S, Davies JR, Requena C et al. High nevus counts confer a favorable prognosis in melanoma patients. Int J Cancer 2015; 137:1691-8.
Ghiasvand R, Robsahm TE, Green AC et al. Association of phenotypic characteristics and UV radiation exposure with risk of melanoma on different body sites. JAMA Dermatol 2019; 155:39-49.

Auteurs

C Dessinioti (C)

1st Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece.

A C Geller (AC)

Department of Social and Behavioral Sciences, Harvard TH School of Public Health, Boston, MA, USA.

A Stergiopoulou (A)

1st Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece.

N Dimou (N)

Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioaninna, Greece.
Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.

S Lo (S)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

U Keim (U)

Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tübingen, Germany.

J E Gershenwald (JE)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center (MD Anderson), Houston, TX, USA.

L E Haydu (LE)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center (MD Anderson), Houston, TX, USA.

R Dummer (R)

Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

J Mangana (J)

Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

A Hauschild (A)

Department of Dermatology and Venerology, University Hospital of Schleswig-Holstein, Kiel, Germany.

F Egberts (F)

Department of Dermatology and Venerology, University Hospital of Schleswig-Holstein, Kiel, Germany.

R Vieira (R)

Coimbra Hospital and Universitary Centre, Coimbra, Portugal.

A Brinca (A)

Coimbra Hospital and Universitary Centre, Coimbra, Portugal.

I Zalaudek (I)

Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
Division of Dermatology and Venerology, Medical University of Graz, Graz, Austria.

T Deinlein (T)

Division of Dermatology and Venerology, Medical University of Graz, Graz, Austria.

E Evangelou (E)

Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioaninna, Greece.
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

J F Thompson (JF)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Royal Prince Alfred Hospital, Camperdown, Sydney, NSW, Australia.

R A Scolyer (RA)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Royal Prince Alfred Hospital, Camperdown, Sydney, NSW, Australia.
New South Wales Health Pathology, Sydney, NSW, Australia.

K Peris (K)

Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Dermatologia, Rome, Italy.
Università Cattolica del Sacro Cuore, Dermatologia, Rome, Italy.

C Garbe (C)

Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tübingen, Germany.

A J Stratigos (AJ)

1st Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH